Skip to main content
SpringerLink
Log in

Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer

  • Chapter
  • First Online:
Impact of Genetic Targets on Cancer Therapy

Part of the book series: Advances in Experimental Medicine and Biology ((volume 779))

Abstract

The treatment of esophagogastric cancer has been rapidly evolving in the past decade. New cytotoxic drugs and targeted agents have been integrated in the therapeutic paradigm. To better understand the tumor biology and to better utilize targeted agents, genetic alterations in esophagogastric cancer have been actively explored. For example, Her2/Neu amplification and expression were observed in gastric and gastroesophageal (GE) junction cancers. Combination of trastuzumab with cytotoxic chemotherapy has demonstrated a survival advantage in patients with Her2/Neu positive gastric cancer. However, the prognosis of advanced esophagogastric cancer remains poor. This is largely attributed to the tumor heterogeneity and poorly understood tumor biology. This article provides a summary of potential genetic targets and the role of novel targeted agents in the treatment of esophagogastric cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070–4.

    Article  PubMed  CAS  Google Scholar 

  2. Altorki NK, Oliveria S, Schrump DS. Epidemiology and molecular biology of Barrett’s adenocarcinoma. Semin Surg Oncol. 1997;13(4):270–80.

    Article  PubMed  CAS  Google Scholar 

  3. Spechler SJ, Robbins AH, Rubins HB, Vincent ME, Heeren T, Doos WG, et al. Adenocarcinoma and Barrett’s esophagus. An overrated risk. Gastroenterology. 1984;87(4):927–33.

    PubMed  CAS  Google Scholar 

  4. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol. 2007;17(1):2–9. Epub 2006/12/23.

    Article  PubMed  Google Scholar 

  5. Siewert JR, Ott K. Are squamous and adenocarcinomas of the esophagus the same disease. Semin Radiat Oncol. 2007;17(1):38–44. Epub 2006/12/23.

    Article  PubMed  Google Scholar 

  6. American Cancer Society: estimated new cases by sex for all sites, U.S. 2007.

    Google Scholar 

  7. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110(6):669–72.

    Article  PubMed  CAS  Google Scholar 

  8. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541–52. Epub 2003/10/07.

    Article  PubMed  CAS  Google Scholar 

  9. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5(4):317–28. Epub 2004/04/20.

    Article  PubMed  CAS  Google Scholar 

  10. Yarden Y, Ullrich A. Growth factor receptor tyrosine kinases. Annu Rev Biochem. 1988;57:443–78. Epub 1988/01/01.

    Article  PubMed  CAS  Google Scholar 

  11. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78. Epub 2006/02/10.

    Article  PubMed  CAS  Google Scholar 

  12. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–39. Epub 2004/05/01.

    Article  PubMed  CAS  Google Scholar 

  13. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786–92. Epub 2005/02/25.

    Article  PubMed  CAS  Google Scholar 

  14. Takehana T, Kunitomo K, Suzuki S, Kono K, Fujii H, Matsumoto Y, et al. Expression of epidermal growth factor receptor in gastric carcinomas. Clin Gastroenterol Hepatol. 2003;1(6):438–45. Epub 2004/03/16.

    Article  PubMed  CAS  Google Scholar 

  15. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, et al. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c-erbB-2 in human gastric cancer. Cancer. 1995;75(Suppl 6):1418–25. Epub 1995/03/15.

    Article  PubMed  CAS  Google Scholar 

  16. Albanell J, Rojo F, Baselga J. Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol. 2001;28(5 Suppl 16):56–66. Epub 2001/11/14.

    Article  PubMed  CAS  Google Scholar 

  17. Kitagawa Y, Ueda M, Ando N, Ozawa S, Shimizu N, Kitajima M. Further evidence for ­prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin Cancer Res. 1996;2(5):909–14. Epub 1996/05/01.

    PubMed  CAS  Google Scholar 

  18. Gibault L, Metges JP, Conan-Charlet V, Lozac’h P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93(1):107–15. Epub 2005/06/30.

    Article  PubMed  CAS  Google Scholar 

  19. Wilkinson NW, Black JD, Roukhadze E, Driscoll D, Smiley S, Hoshi H, et al. Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg. 2004;8(4):448–53. Epub 2004/05/04.

    Article  PubMed  Google Scholar 

  20. Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, et al. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res. 2003;9(17):6461–8. Epub 2003/12/26.

    PubMed  CAS  Google Scholar 

  21. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 2003;57(1):246–54. Epub 2003/08/12.

    Article  PubMed  CAS  Google Scholar 

  22. Gold PJ, Goldman B, Iqbal S, Leichman LP, Zhang W, Lenz HJ, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010;5(9):1472–6. Epub 2010/07/16.

    Article  PubMed  Google Scholar 

  23. Chan JA, Blaszkowsky LS, Enzinger PC, Ryan DP, Abrams TA, Zhu AX, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22(6):1367–73. Epub 2011/01/11.

    Article  PubMed  CAS  Google Scholar 

  24. Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, et al. Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer. 2009;101(8):1261–8. Epub 2009/09/24.

    Article  PubMed  CAS  Google Scholar 

  25. Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, et al. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol. 2011;29(6):626–31. Epub 2011/01/06.

    Article  PubMed  CAS  Google Scholar 

  26. De Vita F, Orditura M, Martinelli E, Vecchione L, Innocenti R, Sileni VC, et al. A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer. 2011;104(3):427–32. Epub 2011/01/20.

    Article  PubMed  Google Scholar 

  27. Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, et al. A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. Cancer. 2011;117(7):1409–14. Epub 2011/03/23.

    Article  PubMed  CAS  Google Scholar 

  28. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–82. Epub 1987/01/09.

    Article  PubMed  CAS  Google Scholar 

  29. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence In Situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009;9:6. Epub 2009/01/09.

    Article  PubMed  Google Scholar 

  30. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. Epub 2010/08/24.

    Article  PubMed  CAS  Google Scholar 

  31. Yan SY, Hu Y, Fan JG, Tao GQ, Lu YM, Cai X, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17(11):1501–6. Epub 2011/04/08.

    Article  PubMed  CAS  Google Scholar 

  32. Begnami MD, Fukuda E, Fregnani JH, Nonogaki S, Montagnini AL, Da Costa Jr WL, et al. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 Are predictors of poor outcome. J Clin Oncol. 2011;29:3030–6.

    Article  PubMed  CAS  Google Scholar 

  33. Shah MA, Janjigian YY, Pauligk C, et al. Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: a U.S. and European international collaborative analysis. J Clin Oncol. 2011;29:(suppl; abstr 4014).

    Google Scholar 

  34. Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, et al. Southwest oncology group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol. 2011;22:2610–5.

    Article  PubMed  CAS  Google Scholar 

  35. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50. Epub 2006/12/15.

    Article  PubMed  CAS  Google Scholar 

  36. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. Epub 2004/06/04.

    Article  PubMed  CAS  Google Scholar 

  37. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76. Epub 2007/12/28.

    Article  PubMed  CAS  Google Scholar 

  38. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–34. Epub 2003/08/02.

    Article  PubMed  CAS  Google Scholar 

  39. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25(29):4536–41. Epub 2007/09/19.

    Article  PubMed  CAS  Google Scholar 

  40. Tanaka T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, et al. Vascular endothelial growth factor C (VEGF-C) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J Exp Clin Cancer Res. 2010;29:83. Epub 2010/06/30.

    Article  PubMed  Google Scholar 

  41. Kozlowski M, Naumnik W, Niklinski J, Milewski R, Dziegielewski P, Laudanski J. Vascular endothelial growth factor C and D expression correlates with lymph node metastasis and poor prognosis in patients with resected esophageal cancer. Neoplasma. 2011;58(4):311–9. Epub 2011/04/28.

    Article  PubMed  CAS  Google Scholar 

  42. Maeda K, Chung YS, Takatsuka S, Ogawa Y, Onoda N, Sawada T, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995;72(2):319–23. Epub 1995/08/01.

    Article  PubMed  CAS  Google Scholar 

  43. Juttner S, Wissmann C, Jons T, Vieth M, Hertel J, Gretschel S, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228–40. Epub 2005/12/14.

    Article  PubMed  Google Scholar 

  44. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201–6. Epub 2006/11/23.

    Article  PubMed  CAS  Google Scholar 

  45. Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29(7):868–74. Epub 2010/12/30.

    Article  PubMed  CAS  Google Scholar 

  46. Kang Y, Ohtsu A, Van Cutsem E, et al. AVAGAST: a randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC). J Clin Oncol. 2010;28:18s (suppl; abstr LBA4007).

    Article  Google Scholar 

  47. Ilson D, Bains M, Rizk N, et al. Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: preliminary safety analysis. J Clin Oncol. 2009;27(15s). suppl; abstr 4573 2009.

    Google Scholar 

  48. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  PubMed  CAS  Google Scholar 

  49. Okines AF, Langley R, Cafferty FH, et al. Preliminary safety data from a randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with gastric or oesophagogastric junction (OGJ) adenocarcinoma. J Clin Oncol. 2010;28(15s) (suppl; abstr 4019).

    Google Scholar 

  50. Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29:1449–58. Epub 2010/05/13.

    Article  PubMed  CAS  Google Scholar 

  51. Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson III AB. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28(18):2947–51.

    Article  PubMed  CAS  Google Scholar 

  52. Kim C, Lee JL, Choi YH, Kang BW, Ryu MH, Chang HM, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30:306–15. Epub 2010/09/15.

    Article  PubMed  CAS  Google Scholar 

  53. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab—an Eastern cooperative oncology group study. Clin Cancer Res. 2008;14(5):1407–12. Epub 2008/03/05.

    Article  PubMed  CAS  Google Scholar 

  54. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol. 2010;28(9):453. Epub 2009/12/17.

    Article  PubMed  CAS  Google Scholar 

  55. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–7. Epub 1997/02/14.

    Article  PubMed  CAS  Google Scholar 

  56. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med. 2001;7(11):1194–201. Epub 2001/11/02.

    Article  PubMed  CAS  Google Scholar 

  57. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319(5860):195–8. Epub 2008/01/12.

    Article  PubMed  CAS  Google Scholar 

  58. Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, et al. Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer. 2006;94(4):524–31. Epub 2006/02/02.

    Article  PubMed  CAS  Google Scholar 

  59. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009;100(3):551–7. Epub 2009/01/22.

    Article  PubMed  CAS  Google Scholar 

  60. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–42. Epub 2007/05/25.

    Article  PubMed  CAS  Google Scholar 

  61. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7. Epub 2009/05/05.

    Article  PubMed  CAS  Google Scholar 

  62. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):518–23. Epub 1993/11/01.

    PubMed  CAS  Google Scholar 

  63. Wu WK, Sung JJ, Yu L, Li ZJ, Chu KM, Cho CH. Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. Biochem Biophys Res Commun. 2008;373(2):330–4. Epub 2008/06/24.

    Article  PubMed  CAS  Google Scholar 

  64. Wu WK, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. Cancer Lett. 2010;295(1):7–16. Epub 2010/04/13.

    Article  PubMed  CAS  Google Scholar 

  65. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8(3):289–93. Epub 2002/03/05.

    Article  PubMed  CAS  Google Scholar 

  66. Pai R, Nakamura T, Moon WS, Tarnawski AS. Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors. FASEB J. 2003;17(12):1640–7. Epub 2003/09/06.

    Article  PubMed  CAS  Google Scholar 

  67. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo XJ, Ramonetti JT, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res. 1996;56(11):2556–60. Epub 1996/06/01.

    PubMed  CAS  Google Scholar 

  68. Govindan R, McLeod H, Mantravadi P, Fineberg N, Helft P, Kesler K, et al. Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park). 2004;18(14 Suppl 14):18–21. Epub 2005/02/03.

    Google Scholar 

  69. Enzinger PC, Mamon H, Choi N, et al. Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally advanced esophageal cancer. 2004 Gastrointestinal Cancer Symposium, abstract 35.

    Google Scholar 

  70. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 2009;27(6):857–71. Epub 2009/01/24.

    Article  PubMed  CAS  Google Scholar 

  71. Yamada Y, Doi T, Muro K, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer: main results. Gastrointestinal cancers symposium, San Francisco January 15–17, 2009.

    Google Scholar 

  72. Lavker RM, Sun TT. Epidermal stem cells: properties, markers, and location. Proc Natl Acad Sci U S A. 2000;97(25):13473–5. Epub 2000/11/23.

    Article  PubMed  CAS  Google Scholar 

  73. Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, et al. A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J Clin Invest. 2008;118(12):3860–9. Epub 2008/11/27.

    PubMed  CAS  Google Scholar 

  74. Hang D, Dong HC, Ning T, Dong B, Hou DL, Xu WG. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus. 2012;25:638–44. Epub 2012/01/13.

    Article  PubMed  CAS  Google Scholar 

  75. Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One. 2011;6(6):e21419. Epub 2011/07/07.

    Article  PubMed  CAS  Google Scholar 

  76. Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, Lord RV. Expression of the putative stem cell marker musashi-1 in Barrett’s esophagus and esophageal adenocarcinoma. Dis Esophagus. 2010;23(7):580–9. Epub 2010/05/13.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

    Yixing Jiang M.D. Ph.D.

Authors
  1. Yixing Jiang M.D. Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yixing Jiang M.D. Ph.D. .

Editor information

Editors and Affiliations

  1. University Drive 500, Hershey, 17033, Pennsylvania, USA

    Wafik S El-Deiry

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Jiang, Y. (2013). Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer. In: El-Deiry, W. (eds) Impact of Genetic Targets on Cancer Therapy. Advances in Experimental Medicine and Biology, vol 779. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-6176-0_3

Download citation

Publish with us

Policies and ethics

Search

Navigation